Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Home›Research›Companies

Companies

Loading
Home›
Research›
Companies›
HDT Bio
AddedFeb 15, 2024
UpdatedJun 18, 2026
HDT Bio

HDT Bio

Pre-Seed

Hdt Bio Corp: Pioneering RNA vaccines and therapeutics since 2017 through innovative research.

HQ
Seattle, WA, US
Founded
2018
Overview
Compare
Fundraising
Employees
Website

Founded in 2017, HDT Bio is dedicated to pioneering RNA vaccines and therapeutics through innovative research. The company focuses on developing advanced RNA vaccine products aimed at treating and preventing infectious diseases and cancers. Utilizing its proprietary LION™ technology, HDT Bio offers solutions with enhanced safety, potency, durability, and manufacturing efficiency. Their core mission is to redefine the global vaccine landscape by leveraging cutting-edge RNA technology.

Notable figures associated with HDT Bio include leading scientists and industry experts who drive the company's research and development efforts. The company has attracted significant attention from investors interested in transformative healthcare technologies. Key achievements include advancing their repRNA vaccine platform to clinical stages, demonstrating potential in both infectious disease prevention and cancer treatment. HDT Bio's impact is marked by its contributions to the field of RNA therapeutics, positioning itself as a significant player in the biotech industry.

HDT Bio - Similar Companies

Innovac Therapeutics logo

Innovac Therapeutics

innovactx.com

Rnaimmune logo

Rnaimmune

rnaimmune.com

Chimeron Bio logo

Chimeron Bio

VaxEquity logo

VaxEquity

Locanabio logo

Locanabio

Silvec Biologics logo

Silvec Biologics

silvec.com

Rnav8 Bio logo

Rnav8 Bio

Korro Bio logo

Korro Bio

korrobio.com

Mercury Bio logo

Mercury Bio

mercurybio.com

Replicate Bioscience logo

Replicate Bioscience

Orbital Therapeutics logo

Orbital Therapeutics

Nano RED logo

Nano RED

Kylin Therapeutics logo

Kylin Therapeutics

Ochre Bio logo

Ochre Bio

ochre-bio.com

Alltrna logo

Alltrna

alltrna.com

HDT Bio - Quick Facts

Who are HDT Bio's competitors?

Companies similar to HDT Bio include Innovac Therapeutics, Rnaimmune, Chimeron Bio and VaxEquity.

When was HDT Bio founded?

HDT Bio was founded in 2018.

Where is HDT Bio's headquarters located?

HDT Bio's headquarters is located in Seattle, WA, US.

When was HDT Bio's last funding round?

HDT Bio's most recent funding round was for $1M (USD) in October 2023.

How much has HDT Bio raised to-date?

As of Oct 4, 2023, HDT Bio has raised a total of $70M (USD).

How many employees does HDT Bio have?

HDT Bio has 52 employees as of Feb 4, 2024.

HDT Bio - Classification

Technology
  • Biotech
Geographic Exposure
  • Global
Model
  • Platform
Revenue
  • Recurring
Customer
  • Enterprise
  • Government
Main Product
  • RNA Vaccines
  • Therapeutics
Tags
  • Healthtech
NAICS
  • 540000Professional, Scientific, and Technical Services
  • 541714Research and Development in Biotechnology (except Nanobiotechnology)
  • 541000Professional, Scientific, and Technical Services
  • 541700Scientific Research and Development Services
  • 541710Research and Development in the Physical, Engineering, and Life Sciences
SIC
  • 8700Engineering, Accounting, Research, Management, And Related Services
  • 8730Research, Development, And Testing Services
  • 8731Commercial Physical and Biological Research
Show 4 more industry codes
NAICS
  • 620000Health Care and Social Assistance
SIC
  • 8000Health Services
  • 8040Offices And Clinics Of Other Health Practitioners
  • 8049Offices And Clinics Of Health Practitioners, Not Elsewhere Classified